

Product Data Sheet



Forigerimod TFA

Cat. No.: HY-105037A

Molecular Formula: $C_{117}H_{181}N_{34}O_{32}PS.xC_{2}HF_{3}O_{2}$

RIHMVYSKR-{pSer}-GKPRGYAFIEY (TFA) Sequence Shortening:

Target: Autophagy RIHMVYSKR-{pSer}-GKPRGYAFIEY (TFA salt)

Pathway: Autophagy

Storage: Sealed storage, away from moisture and light, under nitrogen

> Powder -80°C 2 years -20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light, under nitrogen)

SOLVENT & SOLUBILITY

DMSO: 100 mg/mL (Need ultrasonic) In Vitro

H₂O: 100 mg/mL (Need ultrasonic)

BIOLOGICAL ACTIVITY

Description

Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [1][2][3][4].

In Vivo

Forigerimod TFA (P140) (i.v.; 100 μg in 100 μL saline per mouse) directly acts on chaperone-mediated autophagy, rescues MRL/lpr mice from cellular infiltration and autophagy defects occurring in salivary glands^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	$MRL/lprmice^{[4]}$			
Dosage:	100 μg in 100 μL saline per mouse			
Administration:	Intravenous administration, single			
Result:	Corrected the cell content and distribution in MRL/lpr salivary glands. Corrected the defective of autophagy processes in SGs of MRL/lpr mice.			

REFERENCES

[1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.

[2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701.

[3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann

Rheum Dis. 2013 Nov;72(11):18	830-5.					
[4]. Baihui Li, et al. Rescue of a	utophagy and lysosome de	fects in salivary glands of MRL/lpi	r mice by a therapeutic phosphoper	otide. J Autoimmun. 2018 Jun;90:132-145.		
Caution: Product has not been fully validated for medical applications. For research use only.						
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemE			
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA						

Page 2 of 2 www.MedChemExpress.com